Protocol for a 1‐year randomised, controlled, parallel group, open‐label trial on the effects and feasibility of time‐restricted eating in individuals with type 2 diabetes‐ The REStricted Eating Time in the treatment of type 2 diabetes (RESET2) trial
Study context
- Population
- Individuals with T2D (HbA1c >53 mmol/mol (>7.0%)) and BMI ≥25 kg/m²planned
- Participants
- 160 individuals
- Planned comparison
- Standard care plus time-restricted eating (TRE) vs standard care and habitual living
- Primary endpoint
- HbA1c
- Follow-up
- 3 months and 1 year after randomisation
Methodological detailsparallel-group, open-label, 1-year, Process evaluation of whether TRE functioned as hypothesised, Secondary outcomes: body weight, fat mass, CGM-derived TIR and antidiabetic medicine use at 1 year
- Parallel-group
- Open-label
- 1-year
- Process evaluation of whether TRE functioned as hypothesised
- Secondary outcomes: body weight, fat mass, CGM-derived TIR and antidiabetic medicine use at 1 year
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Protocol for a 1‐year randomised, controlled, parallel group, open‐label trial on the effects and feasibility of time‐restricted eating in individuals with type 2 diabetes‐ The REStricted Eating Time in the treatment of type 2 diabetes (RESET2) trial. Diabet Med. Published 11 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →